Systemic prostacyclin and thromboxane production in obstructive sleep apnea

Advances in Medical Sciences

Volumn 61, Issue 1, 2016, Pages 154-159

  Mejza, Filip ^a   Kania, Aleksander ^a   Nastalek, Pawel ^a   Nizankowska Jedrzejczyk, Agata ^a   Nizankowska Mogilnicka, Ewa ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Continuous positive airway pressure; Obstructive sleep apnea; Prostacyclin; Thromboxane

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; THROMBOXANE B2; PROSTACYCLIN; THROMBOXANE;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BLOOD; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; SLEEP; SLEEP DISORDERED BREATHING; SNORING; URINE; AGED; BIOSYNTHESIS; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED;

6-KETOPROSTAGLANDIN F1 ALPHA; ADULT; AGED; CASE-CONTROL STUDIES; CONTINUOUS POSITIVE AIRWAY PRESSURE; EPOPROSTENOL; FEMALE; HUMANS; MALE; MIDDLE AGED; SLEEP APNEA, OBSTRUCTIVE; THROMBOXANE B2; THROMBOXANES;

EID: 84960131829     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.1016/j.advms.2015.12.001     Document Type: Article

References (27)

1. J.D. Lattimore, D.S. Celermajer, and I. Wilcox Obstructive sleep apnea and cardiovascular disease J Am Coll Cardiol 41 9 2003 1429 1437
2. M. Kato, T. Adachi, Y. Koshino, and V.K. Somers Obstructive sleep apnea and cardiovascular disease Circ J 73 8 2009 1363 1370
3. F.J. Nieto, T.B. Young, B.K. Lind, E. Shahar, J.M. Samet, S. Redline, and et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study JAMA 283 14 2000 1829 1836
4. P.E. Peppard, T. Young, M. Palta, and J. Skatrud Prospective study of the association between sleep-disordered breathing and hypertension N Engl J Med 342 19 2000 1378 1384
5. W.T. McNicholas, and M.R. Bonsigore Management Committee of EU COST ACTION B26. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities Eur Respir J 29 1 2007 156 178
6. O.A. Minai, B. Ricaurte, R. Kaw, J. Hammel, M. Mansour, K. McCarthy, and et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome Am J Cardiol 104 9 2009 1300 1306
7. A.S. Shamsuzzaman, B.J. Gersh, and V.K. Somers Obstructive sleep apnea: implications for cardiac and vascular disease JAMA 290 14 2003 1906 1914
8. C. Selmi, N. Montano, R. Furlan, C.L. Keen, and M.E. Gershwin Inflammation and oxidative stress in obstructive sleep apnea syndrome Exp Biol Med (Maywood) 232 11 2007 1409 1413
9. P. Lévy, M.R. Bonsignore, and J. Eckel Sleep, sleep-disordered breathing and metabolic consequences Eur Respir J 34 1 2009 243 260
10. A. Atkeson, S.Y. Yeh, A. Malhotra, and S. Jelic Endothelial function in obstructive sleep apnea Prog Cardiovasc Dis 51 5 2009 351 362
11. N.A. Bayram, B. Ciftci, T. Keles, T. Durmaz, S. Turhan, E. Bozkurt, and et al. Endothelial function in normotensive men with obstructive sleep apnea before and 6 months after CPAP treatment Sleep 32 10 2009 1257 1263
12. S. Ryan, C.T. Taylor, and W.T. McNicholas Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Postgrad Med J 85 1010 2009 693 698
13. R.J. Gryglewski Prostacyclin among prostanoids Pharmacol Rep 60 1 2008 3 11
14. H. Kimura, M. Niijima, Y. Abe, H. Edo, H. Sakabe, A. Kojima, and et al. Compensatory excretion of prostacyclin and thromboxane metabolites in obstructive sleep apnea syndrome Intern Med 37 2 1998 127 133
15. J. Krieger, D. Benzoni, E. Sforza, and J. Sassard Urinary excretion of prostanoids during sleep in obstructive sleep apnoea patients Clin Exp Pharmacol Physiol 18 8 1991 551 555
16. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force Sleep 22 5 1999 667 689
17. S.I. Said, T. Yoshida, S. Kitamura, and C. Vreim Pulmonary alveolar hypoxia: release of prostaglandins and other humoral mediators Science 185 4157 1974 1181 1183
18. O. Marrone, and M.R. Bonsignore Pulmonary hemodynamics in obstructive sleep apnoea Sleep Med Rev 6 3 2002 175 193
19. Y. Ishii, and S. Kitamura Hyperventilation stimulates the release of prostaglandin I2 and E2 from lung in humans Prostaglandins 39 6 1990 685 691
20. A. Szczeklik, R.J. Gryglewski, J. Szczeklik, and R. Nizankowski Haemodynamic and antihypertensive effect of prostacyclin Adv Exp Med Biol 164 1984 299 305
21. S.L. Dorris, and R.S. Peebles PGI2 as a regulator of inflammatory diseases Mediators Inflamm 2012 2012 926968
22. J.R. Vane, and R.M. Botting Pharmacodynamic profile of prostacyclin Am J Cardiol 75 3 1995 3A 10A
23. E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men Arterioscler Thromb Vasc Biol 23 6 2003 1111 1115
24. J.M. Gerrard, S. Taback, S. Singhroy, J.C. Docherty, I. Kostolansky, A. McNicol, and et al. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 in humans in response to a standardized vascular injury and the influence of aspirin Circulation 79 1 1989 29 38
25. P.H. Vlasses, R.K. Ferguson, J.B. Smith, H.H. Rotmensch, and B.N. Swanson Urinary excretion of prostacyclin and thromboxane A2 metabolites after angiotensin converting enzyme inhibition in hypertensive patients Prostaglandins Leukot Med 11 2 1983 143 150
26. M.A. Konstam, M.R. Weir, A. Reicin, D. Shapiro, R.S. Sperling, E. Barr, and et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib Circulation 104 19 2001 2280 2288
27. D. Mukherjee, S.E. Nissen, and E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 8 2001 954 959